参考文献/References:
[1] KOHLER B A, SHERMAN R L, HOWLADER N, et
al. Annual report to the nation on the status of cancer,
1975-2011, featuring incidence of breast cancer subtypes
by race/ethnicity, poverty, and state[J]. Journal of
the National Cancer Institute, 2015, 107(6): 36-38.
[2] 肖小平,郭 玲,张 熊. 胆管癌组织LOXL2 mRNA
与Tenascinm-C mRNA 表达的临床应用研究[J]. 现
代检验医学杂志, 2017, 32(3):79-81.
XIAO Xiaoping, GUO Ling, ZHANG Xiong. Clinical
application of the expression of LOXL2 mRNA and
tenascin-C mRNA in tissues of the bile duct cancer[J],
Journal of Modern Laboratory Medicine, 2017,
32(3):79-81.
[3] 周晓冬, 刘会利, 赵汉东, 等. 原发性胆汁性胆管炎
患者血清自身抗体及生化指标的特征分析[J]. 现代
检验医学杂志, 2016, 31(6):32-36.
ZHOU Xiaodong, LIU Huili, ZHAO Handong, et al.
Characteristic analysis of sera of autoantibodies and
biochemical indexes of patients with primary biliary
cholangitis[J], Journal of Modern Laboratory Medicine,
2016, 31(6):32-36.
[4] 侯建峰, 杨亚明, 王 莉, 等. 谷氨酸脱氢酶在肝外胆
管癌患者肿瘤组织中的表达及其临床意义[J]. 现代
检验医学杂志, 2018, 33(6):13-16,20.
HOU Jianfeng, YANG Yaming, WANG Li, et al. Expression
and clinical significance of glutamate dehydrogenase
in tumor tissues of patients with extrahepatic
cholangiocarcinoma[J], Journal of Modern Laboratory
Medicine, 2018, 33(6):13-16,20.
[5] 李媛,胡正军. 髓源性抑制细胞- 免疫系统的调节成
分[J]. 现代检验医学杂志, 2011, 26(2):58-61.
LI Yuan, HU Zhengjun. Myeloid-derived suppressor
cells-regulatory components of the immune system[J].
Journal of Modern Laboratory Medicine, 2011,
26(2):58-61.
[6] KEISARI Y. Tumor abolition and antitumor immunostimulation
by physico-chemical tumor ablation[J].
Frontiers in Bioscience, 2017, 22:310-347.
[7] MOHME M, RIETHDORF S, PANTEL K.et al. Circulating
and disseminated tumour cells - mechanisms of
immune surveillance and escape[J]. Nature Reviews
Clinical Oncology, 2017, 14(3): 155-167.
[8] MARTIN O A, ANDERSON R L, NARAYAN K, et
al. Does the mobilization of circulating tumour cells
during cancer therapy cause metastasis?[J]. Nature Reviews
Clinical Oncology, 2017, 14(1): 32-44.
[9] 陈琬玲,朱旭,师娟, 等. 非小细胞肺癌肿瘤微环境
中IFN-γ,TGF-β, IDO 表达变化及其相关性[J]. 中
国肿瘤生物治疗杂志, 2016, 23(4): 510-514.
CHEN Wanling, ZHU Xu, SHI Juan, et al. Expression
changes of IFN-γ, TGF-β1 and IDO and their correlation
in the tumor microenvironment of non-small cell
lung cancer[J]. Chinese Journal of Cancer Biotherapy,
2016, 23(4): 510-514.
[10] SABATIER R, FINETTI P, MAMESSIER E, et al.
Prognostic and predictive value of PDL1 expression
in breast cancer [J]. Oncotarget, 2015, 6(7): 5449-
5464.
[11] WANG Yiwei, WANG Hang, ZHAO Qi, et al. PD-L1
induces epithelial-to-mesenchymal transition via activating
SREBP-1c in renal cell carcinoma[J]. Medical
Oncology, 2015, 32(8):212.
[12] GOLDFINGER M, XU Mina, BERTINO J R, et al.
Checking in on lenalidomide in diffuse large B cell
lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2019,
19(6): e307- e311.
[13] WANG Liang, WANG Hua, CHEN Hao, et al. Serum
levels of soluble programmed death ligand 1 predict
treatment response and progression free survival in
multiple myeloma [J]. Oncotarget, 2015, 6(38): 41228-
41236.
[14] HU Bo, YANG Xinrong, XU Yang, et al. Systemic
immune- inflammation index predicts prognosis of
patients after curative resection for hepatocellular carcinoma
[J]. Clinical Cancer Research, 2014, 20(23):
6212-6222.
[15] HANSEN M H, HURWIT W Z N, MADOW W G.
Sample survey methods and theory[M]. New York:John
wiley and Sons. Inc,1953.
[16] 蒋涛, 王永武. 免疫检测点抑制剂治疗非小细胞肺癌
[J]. 外科研究与新技术, 2014, 3(2): 145-148.
JIANG Tao, WANG Yongwu. Immune checkpoint inhibitors
for the treatment of non-small cell lung cancer [J]. Surgical
Research and New Technique, 2014, 3(2): 145-148.
[17] 艾斌. 免疫检查点抑制剂在肿瘤治疗中的应用[J]. 医
学与哲学, 2015, 36(4): 18-21.
AI Bin. The treatment of malignant tumor by immune
checkpoint inhibitors[J]. Medicine & Philosophy, 2015,
36(4): 18-21.
[18] FRIDMAN W H, ZITVOGEL L, SAUT?S–FRIDMANV
C, et al. The immune contexture in cancer
prognosis and treatment[J]. Nature Reviews Clinical
Oncology, 2017,14(12):717-734.
[19] FENG Mengyu, Xiong Guangbing, CAO Zhe, et
al. PD-1/PD-L1 and immunotherapy for pancreatic
cancer[J]. Cancer Letters, 2017, 407:57-65.
[20] 徐金良, 杜丹丹, 翟志敏, 等. 卵巢良恶性肿瘤患者血
液NLR,LMR,RDW,PLR 四项参数的变化及其临床意
义[J]. 现代检验医学杂志, 2018, 33(2): 16-18,22.
XU Jinliang, DU Dandan, ZHAI Zhimin, et al.Changes
and clinical significance of four parameters of
NLR,LMR, RDW and PLR in patients with benign and
malignant ovarian tumors[J]. Journal of Modern Laboratory
Medicine, 2018, 33(2): 16-18.
[21] OTTENHOF S R, DJAJADININGRAT R S, THYGESEN
H H, et al. The prognostic value of immune
factors in the tumor microenvironment of penile squamous
cell carcinoma [J]. Front Immunol, 2018,9:1253.
[22] SABATIER R, FINETTI P, MAMESSIER E, et al.
Prognostic and predictive value of PDL1 expression in
breast cancer [J]. Oncotarget, 2015, 6(7): 5449-5464.
[23] POSTOW M A, CALLAHAN M K, WOLCHOK J D.
Immune checkpoint blockade in cancer therapy [J].
Journal of Clinical Oncology, 2015, 33(17): 1974-1982.
[24] 潘佳佳,贾晓青,黄岗, 等. PD-1/PD-Ls 信号通路
及其抗体在肿瘤治疗中的应用[J]. 中国药科大学学
报, 2016, 47(1): 9-18.
PAN Jiajia, JIA Xiaoqing, HUANG Gang, et al. PD-1/
PD-Ls signal pathway and the application of anti-PD-1/
PD-Ls antibodies in cancer therapy[J]. Journal of China
Pharmaceutical University, 2016, 47(1): 9-18.
[25] BULIAN P,SHANAFELT T D,FEGAN C, et al.
CD49d is the strongest flow cytometry-based predictor
of overall survival in chronic lymphocytic leukemia
[J]. Journal of Clinical Oncology, 2014, 32(9):
897-904.
[26] CHINEN LTD, ABDALLAH E A, BRAUN A C, et
al. circulating tumor cells as cancer biomarkers in the
clinic[J]. Adv Exp Med Biol, 2017, 994:1-41.